Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 10, 2008, Pages 971-981

  Freeman, Bradley D ^a   Dixon, David J ^a   Coopersmith, Craig M ^a   Zehnbauer, Barbara A ^a   Buchman, Timothy G ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Arrhythmia; Critical care; Database; Drug toxicity; Intensive care; Pharmacoepidemiology

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIESTROGEN; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; ECHO CONTRAST MEDIUM; HALOPERIDOL; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; MACROLIDE; MOOD STABILIZER; NEUROLEPTIC AGENT; OPIATE AGONIST; PHOSPHODIESTERASE INHIBITOR; PSYCHOTROPIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOMATOSTATIN DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY TRACT DISEASE; SEX RATIO; TORSADE DES POINTES;

CARDIOVASCULAR AGENTS; CRITICAL ILLNESS; DATABASES, FACTUAL; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; TORSADES DE POINTES;

EID: 57649237613     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1637     Document Type: Article

References (32)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
2. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003; 114: 135-141.
3. Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval. J Am Med Assoc 2003; 289: 2120-2127.
4. Arizona Center for Education and Research on Therapeutics. www.arizonacert.org [accessed 16 April 2008].
5. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride. Impact of food and drug administration regulatory action. J Am Med Assoc 2000; 284: 3036-3039.
6. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc 2002; 287: 2215-2220.
7. Zelster D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsades de points due to noncardiac drugs. Medicine 2003; 82: 282-290.
8. De Ponti F, Poluzzi E, Montanaro N. Organizing evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185-209.
9. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089-1096.
10. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161-1167.
11. Straus SMJM, Bleumink GS, Dieleman JP, et al. Antipsychotics and risk of sudden cardiac death. Arch Intern Med 2004; 164: 1293-1297.
12. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002; 180: 515-522.
13. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QT-interval, torsades de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782.
14. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrythmia in patients taking antipsychotic drugs: cohort study using administrative data. Br Med J 2002; 325: 1070-1075.
15. Freeman BD, McLeod HL. Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov 2004; 3: 88-93.
16. Cerner Corporation. ckn.cerner.com [accessed 20 May 2008].
17. Freeman BD, Borecki IB, Coopersmith CM, Buchman TB. Relationship between tracheostomy timing and duration of mechanical ventilation in critically ill patients. Crit Care Med 2005; 2005. 33: 2513-2520.
18. Rapoport J, Teres D, Steingrub J, Higgins T, McGee W, Lemeshow S. Patient characteristics and ICU organizational factors that influence frequency of pulmonary artery catheterization. J Am Med Assoc 2000; 283: 2557-2567.
19. Glance LG, Osler TM, Dick AW. Identifying quality outliers in a large, multiple institution database by using customized version of the simplified acute physiology score II and the mortality probability model II. Crit Care Med 2002; 30: 1995-2002.
20. Higgins TL, McGee WT, Steingrub JS, Rapoport J, Lemeshow S, Teres D. Early predictors of prolonged intensive care unit stay: Impact of illness severity, physician staffing, and preintensive care unit length of stay. Crit Care Med 2003; 31: 45-51.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-828.
22. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci 2000; 97: 10613-10618.
23. Splwaski I, TimothyKW, Tateyama M, et al. Variant of SCN5A Sodium Channel implicated in risk of cardiac arrhythmia. Science 2002; 297: 1333-1336.
24. Cook SF, Visscher WA, Hobbs CL, Williams RL. Projct IMPACT: results from a pilot validity study of a new observational database. Crit Care Med 2002; 30: 2765-2770.
25. Roden DM. Antiarrhythmic drugs. In Hardman JG, Limbird LL (eds). The Pharmacological Basis of Therapeutics (10th edn). McGraw-Hill: New York, 2001; 933-970.
26. Avorn J. In defense of pharmacoepidemiology - embracing the Yin and Yang of drug research. N Engl J Med 2007; 357: 2219-2221.
27. Psaty BM, Burke SP. Protecting the health of the public - institute of medicine recommendations on drug safety. N Engl J Med 2007; 355: 1753-1755.
28. Roden DM. An under-recognized challenge in evaluating post-marketing drug safety. Circulation 2005; 111: 246-248
29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
30. Freeman BD, Danner RL, Banks S, Natanson C. Safeguarding patients in clinical trials with high mortality rates. Am J Respir Crit Care Med 2001; 164: 190-192.
31. Palazzo M, Soni N. Critical care studies: redefining the rules. Lancet 1999; 352: 1306-1307.
32. Stafford RS. Regulating off-label drug use - rethinking the role of the FDA. N Engl J Med 2008; 358: 1427-1429.